Francesco Bibbiani

2.3k citations

34 papers · 1.9k indexed · h-index 17

Cellular and Molecular Neuroscience top 2%
Neurology top 1%
Psychiatry and Mental health top 2%
Pediatrics, Perinatology and Child Health top 5%
Physiology top 1%

Co-authors: Thomas N. Chase Justin D. Oh William Bara‐Jimenez Tzvetelina Dimitrova M. Maral Mouradian Michael J. Morris Gregory L. Krauss Anna Patten
Topics: Epilepsy research and treatment (14 papers)Neurological disorders and treatments (13 papers)Parkinson's Disease Mechanisms and Treatments (12 papers)
Cited by: Physiology Neurology Cellular and Molecular Neuroscience
Journals: Blood Hepatology Neurology
Partner nations: United States United Kingdom Australia

In The Last Decade

Francesco Bibbiani

32 papers receiving 1.8k citations

Peers

Countries citing papers authored by Francesco Bibbiani

Since Specialization

Citations

This map shows the geographic impact of Francesco Bibbiani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Bibbiani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Bibbiani more than expected).

Fields of papers citing papers by Francesco Bibbiani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Bibbiani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Bibbiani. The network helps show where Francesco Bibbiani may publish in the future.

Co-authorship network of co-authors of Francesco Bibbiani

This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Bibbiani. A scholar is included among the top collaborators of Francesco Bibbiani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Bibbiani. Francesco Bibbiani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ataluren Delays Loss of Ambulation and Decline in Pulmonary Function in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (2553) 2021 ·Neurology ·Craig M. McDonald,Francesco Muntoni,Mark Rance,Joel Jiang,Allan Kristensen,(unknown),Francesco Bibbiani,Elizabeth Goodwin,Heather Gordish‐Dressman,Lauren P. Morgenroth,(unknown),Panayiota Trifillis,M. Tulinius	1
2	Superiority of Avatrombopag to Placebo in Increasing Platelet Counts in Patients with Chronic Liver Disease-Associated Thrombocytopenia Undergoing Scheduled Procedures: Results from 2, Phase 3 Randomized Studies 2017 ·Blood ·Norah A. Terrault,David J. Kuter,Namiki Izumi,Zeid Kayali,Paul Mitruț,Won Young Tak,Francesco Bibbiani	5
3	Superiority of Avatrombopag (AVA) to Placebo (PBO) for the Treatment of Chronic Liver Disease (CLD)-Associated Thrombocytopenia (TCP) in Patients Undergoing Scheduled Procedures: Results of 2 Randomized, PBO-Controlled Phase 3 Studies 2017 ·Hepatology ·Norah A. Terrault,Francesco Bibbiani,Yi‐Cheng Chen,Namiki Izumi,Zeid Kayali,José R. Soto,Paul Mitruț,Won Young Tak,Tarek Hassanein	2
4	Dosing considerations for rufinamide in patients with Lennox–Gastaut syndrome: Phase III trial results and real-world clinical data 2017 ·Seizure ·Sanjeev V. Kothare,Gerhard Kluger,Rajesh Sachdeo,Betsy Williams,(unknown),Carlos Perdomo,Francesco Bibbiani	12
5	MYOCLONIC AND ABSENCE SEIZURES IN PATIENTS WITH IDIOPATHIC GENERALIZED EPILEPSY (IGE): EXPLORATORY OUTCOMES IN A PHASE III PGTC STUDY WITH ADJUNCTIVE PERAMPANEL 2016 ·Epilepsia ·TJ O'Brien,B. J. Steinhoff,Antonio Laurenza,Anna Patten,Francesco Bibbiani,(unknown)	1
6	Efficacy of Adjunctive Perampanel in Idiopathic Generalized Epilepsy Patients with Drug-Resistant Primary Generalized Tonic-Clonic Seizures by Age, Sex, and Race: Double-Blind Placebo-Controlled Phase III Study (P2.021) 2016 ·Neurology ·Bernhard J. Steinhoff,Terence J. O’Brien,Haichen Yang,Antonio Laurenza,Anna Patten,Francesco Bibbiani	0
7	Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study 2016 ·European Journal of Paediatric Neurology ·Alexis Arzimanoglou,José Alexandre Ferreira,Andrew Satlin,(unknown),Betsy Williams,David Critchley,Edgar Schuck,Ziad Hussein,Dinesh Kumar,Shobha Dhadda,Francesco Bibbiani	29
8	Adjunctive Perampanel for the Treatment of Drug-Resistant Primary Generalized Tonic-Clonic (PGTC) Seizures in Patients with Idiopathic Generalized Epilepsy (IGE): A Double-Blind, Randomized, Placebo-Controlled Phase III Trial (S31.007) 2015 ·Neurology ·Jacqueline A. French,Gregory L. Krauss,Robert Wechsler,Xuefeng Wang,Bree DiVentura,Christian Brandt,Eugen Trinka,Terence J. O’Brien,Antonio Laurenza,Anna Patten,Francesco Bibbiani	11
9	Perampanel in Parkinson Disease Fluctuations 2012 ·Clinical Neuropharmacology ·Olivier Rascol,Paolo Barone,Madhuri Behari,Murat Emre,Nir Giladi,C. Warren Olanow,Evžen Růžička,Francesco Bibbiani,David Squillacote,Anna Patten,Eduardo Tolosa	45
10	Bioavailability of Three Rufinamide Oral Suspensions Compared With the Marketed 400-mg Tablet Formulation: Results From a Randomized-Sequence, Open-Label, Four-Period, Four-Sequence Crossover Study in Healthy Subjects 2011 ·Clinical Therapeutics ·David Critchley,Jagadeesh Aluri,Peter D. W. Boyd,(unknown),Milind M. Narurkar,(unknown),Francesco Bibbiani	8
11	Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease 2011 ·BMC Neurology ·Martin R. Farlow,Felix Veloso,Margaret Moline,Jane Yardley,Elimor Brand‐Schieber,Francesco Bibbiani,Heng Zou,Timothy Hsu,Andrew Satlin	65
12	A randomized, double‐blind, placebo‐controlled, parallel‐group study of rufinamide as adjunctive therapy for refractory partial‐onset seizures 2010 ·Epilepsia ·Victor Biton,Gregory L. Krauss,(unknown),Francesco Bibbiani,Allison Mann,Carlos Perdomo,Milind M. Narurkar	47
13	A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model 2008 ·Pharmacology Biochemistry and Behavior ·K.E. Vanover,Adrienne J. Betz,Stephen G. Weber,Francesco Bibbiani,(unknown),David M. Weiner,Roger J. Davis,Thomas N. Chase,John D. Salamone	65
14	Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates 2006 ·Neuropharmacology ·(unknown),Justin D. Oh,Francesco Bibbiani,Mahlon Collins,Irene Avila,Thomas N. Chase	15
15	Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD 2005 ·Experimental Neurology ·Francesco Bibbiani,Justin D. Oh,(unknown),Mahlon Collins,(unknown),Thomas N. Chase	98
16	Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease 2005 ·Movement Disorders ·William Bara‐Jimenez,Francesco Bibbiani,Michael J. Morris,Tzvetelina Dimitrova,Abdullah Sherzai,M. Maral Mouradian,Thomas N. Chase	137
17	Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates 2005 ·Experimental Neurology ·Francesco Bibbiani,Lauren C. Costantini,Raj Patel,Thomas N. Chase	106
18	Striatal glutamatergic mechanisms and extrapyramidal movement disorders 2003 ·Neurotoxicity Research ·Thomas N. Chase,Francesco Bibbiani,Justin D. Oh	64
19	Quetiapine Attenuates Levodopa-Induced Motor Complications in Rodent and Primate Parkinsonian Models 2002 ·Experimental Neurology ·Justin D. Oh,Francesco Bibbiani,Thomas N. Chase	57
20	Continuous Transdermal Dopaminergic Stimulation in Advanced Parkinson's Disease 2001 ·Clinical Neuropharmacology ·Leo Verhagen Metman,(unknown),Carrie M. Farmer,Francesco Bibbiani,Spiridon Konitsiotis,Michael J. Morris,Holly A. Shill,William Bara‐Jimenez,M. Maral Mouradian,Thomas N. Chase	78

About Francesco Bibbiani

Francesco Bibbiani is a scholar working on Neurology, Psychiatry and Mental health and Cellular and Molecular Neuroscience, having authored 34 papers that have together received 1.9k indexed citations. Recurring topics across this work include Epilepsy research and treatment (14 papers), Neurological disorders and treatments (13 papers) and Parkinson's Disease Mechanisms and Treatments (12 papers). The work is most often cited by research in Physiology (313 citations), Neurology (1.0k citations) and Cellular and Molecular Neuroscience (1.1k citations). Francesco Bibbiani has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Thomas N. Chase, Justin D. Oh, William Bara‐Jimenez, Tzvetelina Dimitrova, M. Maral Mouradian, Michael J. Morris, Gregory L. Krauss, Anna Patten, Antonella Favit and Ayesha Sherzai. Their work appears in journals such as Blood, Hepatology and Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact